TxCell - Tr1 pathway to cure immune diseases

June, 2010: TxCell announces the successfull completion of the Preclinical Development of TX-RAD in Inflammatory Arthritis

April, 2010: TxCell announces Positive Preliminary Results from the Phase I/IIa clinical trial of OvaSave in Crohn's Disease

January, 2010: TxCell appoints Miguel Forte Chief Medical Officer

July, 2009: The collaboration project with TxCell, TcLand, INSERM U844/CHRU Montpellier, has been approuved by the French Public Institutions for the development of Tr1 cell-based technology in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.

August 24-25, 2010
Cellular Therapy Summit
Edinburgh, Scotland
More information here

September 11-14, 2010
International Society for Cellular Therapy
Europe 2nd Regional Meeting
Lago Maggiore
Belgirate, Italy
More information here

New approach in immunosuppressive strategies

Txcell strategy is to develop investigational products in a new class of autologous cellular immunotherapies that are uniquely designed to regulate the patient's own immune system.

Autologous cellular immunotherapies hold promise because they may provide patients meaningful clinical benefits with low toxicity.

TxCell develops innovative treatments for Crohn's (phase I/IIa) and Rheumatoid Arthritis patients (pre-clinical stage).

TxCell is a spin-off from the French Medical Research Institute (INSERM) .

[ Retour ]

TxCell Science Video Click to Enlarge

A new TxCell publication
released in 2009